Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tergenpumatucel-L vs Docetaxel in NSCLC
NCT01774578Phase 3Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Feb 2013
- Primary completion
- May 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tergenpumatucel-l in non-small cell lung cancer (NSCLC), sponsored by Lumos Pharma, Inc. Primary endpoint: Overall Survival at 19 months. Started Feb 2013; status: terminated.
02
Drugs
tergenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01774578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774578.